Nasdaq

BridgeBio reports open-label extension data on acoramidis in ATTR-CM

BridgeBio (BBIO) Pharma presented initial outcomes from the ATTRibute-CM open-label extension study of acoramidis in ATTR-CM at the American Heart Association Scientific Sessions. ATTRibute-CM was ...
Seeking Alpha

Acoramidis Demonstrates Statistically Significant Reduction in Cardiovascular Mortality (CVM) through Month 42 of the ATTRibute-CM Open Label Extension

- Acoramidis demonstrated a significant reduction in risk of CVM through 42 months post-randomization, with a 44% hazard reduction, setting a new standard for CVM outcomes for patients with ATTR-CM - ...
Seeking Alpha

BridgeBio to Present Outcomes Data Through 42 Months from the Open-Label Extension of ATTRibute-CM, the Phase 3 Study of Acoramidis for Treatment of ATTR-CM, at 2024 AHA ...

PALO ALTO, Calif., Oct. 03, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases, announced ...
Morningstar

BridgeBio to Present Additional Open-label Extension Data from ATTRibute-CM at ESC Congress 2025

PALO ALTO, Calif., Aug. 25, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, ...